Liquid Biopsy in Cancer Management: An Empirical Analysis of Awareness, Efficacy, and Adoption Barriers

Background: Liquid biopsy is one of the revolutionary and minimally invasive methods in the sphere of oncology that allows detecting and tracking cancer by employing circulating tumor DNA and circulating tumor cells as the biomarkers. It has immense benefits as compared to conventional tissue biopsy, such as real-time monitoring and reduced risk to the patient. Although this issue is increasingly becoming important, it still differs in awareness and acceptance across various groups of people and thus requires an empirical study. Objective: The proposed study is designed to discuss the role of liquid biopsies in the diagnosis and monitoring of cancer by assessing consciousness, perceived efficacy, benefits, difficulties, and future opportunities, and how they can affect the perception in general. Methodology: In the study, a structured questionnaire was used with 200 respondents (medical professionals, researchers, and students) as the quantitative, cross-sectional research design. The collection of data was done in a five-point Likert scale, with statistical analysis done in SPSS, including descriptive statistics, normality test, Cronbach's alpha test of reliability, KMO, Bartlett test of validity, Pearson correlation, regression analysis, t-test, one-way ANOVA, Kruskal-Wallis test, and Chi-square test. Results: The results indicated that the data were normally distributed, dependable, and valid. The analysis of correlation showed that all the variables have strong positive relationships. Through regression analysis, it was established that awareness, effectiveness, monitoring, advantages, challenges, and future potential are important and have a positive impact on overall perception. Significant differences and associations among demographic variables (age and gender) were verified with the help of the inferential tests. Conclusion: The paper has concluded that liquid biopsy is a very promising instrument in the diagnosis and monitoring of cancer, which is highly accepted due to its non-invasive, clinical, and potential. Nevertheless, in a bid to ensure its wide adoption, the issues of cost, sensitivity, and standardization need to be addressed. These findings have significant implications for healthcare professionals, researchers, and policymakers to facilitate the use of liquid biopsy in normal clinical practice.

Перевод пока недоступен